Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
about
Which anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsPharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachA meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.The placebo effect in overactive bladder syndrome.Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study.An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjectsThe role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects.Tolterodine for the treatment of overactive bladder: a review.Nocturia in relation to sleep, health, and medical treatment in the elderly.Role of muscarinic receptor antagonists in urgency and nocturia.The emergence of new drugs for overactive bladder.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.Developments in pharmacological therapy for the overactive bladder.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.A review of solifenacin in the treatment of urinary incontinence.Management of overactive bladder syndromeAgents for treatment of overactive bladder: a therapeutic class review.Overactive bladder - 18 years - Part IIEfficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.Solifenacin at 3 years: a review of efficacy and safety.Role of fesoterodine in the treatment of overactive bladder.Basic mechanisms of urgency: roles and benefits of pharmacotherapyEfficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.Urinary incontinence: pharmacotherapy options.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Solifenacin for overactive bladder: a systematic review and meta-analysis.Solifenacin: pharmacology and clinical efficacy.Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.Emerging drugs for overactive bladder.What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial.Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.Detrusor after-contraction on ambulatory urodynamics in symptomatic women.
P2860
Q24203880-F449B355-6150-4920-9BDB-CBDE00ECF56BQ24243870-6582F5C0-1D72-4DBC-9142-36D29B5DB104Q28275473-22306F8C-46C3-4EC7-AFF0-C81F1D45EBDEQ28742444-A4F992BC-B68C-4EE4-919C-B7BC7A394856Q33485538-20A7297B-CEC0-4154-8FAE-17416D53D652Q34197411-81A1EE16-FAE0-427C-9F3A-9C3F65814F5DQ34569114-1887E054-AF7A-49C6-8AE0-FC0BDF144795Q34569361-969C99C8-4B29-4D8A-9474-A6A829372656Q35042588-98BD1944-FAF3-4B38-AB63-77CF2485AF6CQ35629770-1DB88A95-13F6-403D-BA02-159A37A076EBQ36023698-B17A0C48-D784-4FDC-BC9B-F691E221E100Q36150735-F76736A5-F137-4CBF-B896-236FD493C8A7Q36219827-65D8E95F-2EA3-49C3-8DCF-3A0EB749A72CQ36219834-17250C7B-0924-46D7-932B-DE59A57AC15FQ36407417-9700DEC0-7DF5-43E1-8C32-F05957D96FD9Q36428471-FAC01710-ED36-407D-AA7F-E282541C8BD7Q36528534-ECB843EB-41BC-4553-99BB-A62CDF46AA64Q36566857-19B38DC5-D60F-4924-AFF0-9BB30E519FEEQ36655193-CB6AFA29-25F7-425B-8C12-A737D8AEA789Q36822864-89C7220F-DE4C-491E-95FA-9485BF34F5A7Q36875672-180726E9-F59B-4BD5-A3FE-8EFCFA360350Q36885443-8C5E2C2A-2177-4BB6-B0B0-E6B001CAD6D7Q36912766-52219316-880E-458F-83FE-458774DC27E5Q37187453-92800B5E-093A-4BB2-A75D-BA087A093FBEQ37226401-DF3182DD-0028-496D-9794-ED5BDE08B19CQ37283542-B116FF37-0FB0-465D-BE43-B9EA6620E4F9Q37428717-62F6D196-48E0-4B1F-97FA-885C3BE606EFQ37570247-8935953C-9AFB-4D34-BADC-A095C99B2C89Q37884579-6B996322-EA50-453A-9724-9875E9F73C8CQ37914849-987B9AC5-C46B-4F4D-A574-0C6B069CA6BDQ37981898-E1B830CE-DEF5-468B-A908-A8EFDF428FC5Q38177369-AD720C4F-F6AD-4EB8-82B6-C7E81F7E474EQ38400412-E69F7B98-941A-45DE-BD08-4A650B7DFECDQ38584641-18B33285-AA54-4C6F-B99E-4696E8CD56FBQ38731389-A76B8861-5280-4F59-A579-367A0C6F4468Q39020998-7A6620DD-2FB1-43D1-A896-D336FCD44E16Q39412362-EE76E773-17AE-433C-A262-96869387AA4BQ39450968-EA233F31-553A-4364-9D6A-8C38323C55F5Q39816197-60910420-2F7A-476B-B766-D3859448B2A4Q41458891-4B4C6D3E-7442-4ED8-B430-20BE81EFF13C
P2860
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@ast
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@en
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@nl
type
label
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@ast
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@en
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@nl
prefLabel
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@ast
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@en
Solifenacin appears effective ...... ed phase 2 dose-finding study.
@nl
P2093
P2860
P1433
P1476
Solifenacin appears effective ...... led phase 2 dose-finding study
@en
P2093
A E J L Kramer
A M Ridder
J L H R Bosch
P2860
P356
10.1111/J.1464-410X.2004.04561.X
P577
2004-01-01T00:00:00Z